Schizophrenia-relevant behaviours in a genetic mouse model for Y2 deficiency

Behavioural Brain Research

Volumn 207, Issue 2, 2010, Pages 434-440

  Karl, Tim ^a,b,c   Chesworth, Rose ^a,b,c   Duffy, Liesl ^a,b   Herzog, Herbert ^a  

^a GARVAN INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c NEUROSCIENCE RESEARCH AUSTRALIA   (Australia)

Author keywords

Neuropeptide Y; Schizophrenia; Sensorimotor gating; Sex; Social interaction; Y2 knockout mouse

Indexed keywords

DEXAMPHETAMINE; DIZOCILPINE; NEUROPEPTIDE Y2 RECEPTOR;

ACOUSTIC REFLEX; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; FEMALE; GENETIC MODEL; HYPERACTIVITY; LOCOMOTION; MALE; MENTAL PERFORMANCE; MOUSE; NONHUMAN; PHENOTYPE; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN DEPLETION; PSYCHOSOCIAL WITHDRAWAL; REFERENCE MEMORY; SCHIZOPHRENIA; SENSORIMOTOR FUNCTION; SEX DIFFERENCE; SOCIAL INTERACTION; STARTLE REFLEX; WORKING MEMORY;

ANIMALS; BEHAVIOR, ANIMAL; COGNITION; DEXTROAMPHETAMINE; DISEASE MODELS, ANIMAL; DIZOCILPINE MALEATE; FEMALE; IMPULSIVE BEHAVIOR; MALE; MEMORY, SHORT-TERM; MICE; MICE, TRANSGENIC; MOTOR ACTIVITY; NEUROPSYCHOLOGICAL TESTS; PSYCHOTROPIC DRUGS; RECEPTORS, NEUROPEPTIDE Y; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX CHARACTERISTICS; SOCIAL BEHAVIOR;

EID: 74449087907     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2009.10.029     Document Type: Article

References (47)

1. Abi-Dargham A. Do we still believe in the dopamine hypothesis? New data bring new evidence. Int J Neuropsychopharmacol 7 Suppl. 1 (2004) S1-5
2. Baldock P.A., Sainsbury A., Couzens M., Enriquez R.F., Thomas G.P., Gardiner E.M., et al. Hypothalamic Y2 receptors regulate bone formation. J Clin Invest 109 (2002) 915-921
3. Bayer T.A., Falkai P., and Maier W. Genetic and non-genetic vulnerability factors in schizophrenia: the basis of the "two hit hypothesis. J Psychiatr Res 33 (1999) 543-548
4. Bovet D., Renzi P., and Oliverio A. Transfer of responding between different stimuli in rats trained in two avoidance tasks. Life Sci 8 (1969) 575-582
5. Braff D.L., Geyer M.A., and Swerdlow N.R. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156 (2001) 234-258
6. Brocco M., Dekeyne A., Veiga S., Girardon S., and Millan M.J. Induction of hyperlocomotion in mice exposed to a novel environment by inhibition of serotonin reuptake. A pharmacological characterization of diverse classes of antidepressant agents. Pharmacol Biochem Behav 71 (2002) 667-680
7. Chartoff E.H., Heusner C.L., and Palmiter R.D. Dopamine is not required for the hyperlocomotor response to NMDA receptor antagonists. Neuropsychopharmacology 30 (2005) 1324-1333
8. Choi K.H., Elashoff M., Higgs B.W., Song J., Kim S., Sabunciyan S., et al. Putative psychosis genes in the prefrontal cortex: combined analysis of gene expression microarrays. BMC Psychiatry 8 (2008) 87
9. Colmers W.F., and Bleakman D. Effects of neuropeptide Y on the electrical properties of neurons. Trends Neurosci 17 (1994) 373-379
10. Colmers W.F., Lukowiak K., and Pittman Q.J. Presynaptic action of neuropeptide Y in area CA1 of the rat hippocampal slice. J Physiol 383 (1987) 285-299
11. Corbett R., Hartman H., Kerman L.L., Woods A.T., Strupczewski J.T., Helsley G.C., et al. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 45 (1993) 9-17
12. Crawley J.N. Exploratory behavior models of anxiety in mice. Neurosci Biobehav Rev 9 (1985) 37-44
13. Crawley J.N. Behavioral phenotyping of transgenic and knockout mice: experimental design and evaluation of general health, sensory functions, motor abilities, and specific behavioral tests. Brain Res 835 (1999) 18-26
14. Crawley J.N., Belknap J.K., Collins A., Crabbe J.C., Frankel W., Henderson N., et al. Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology (Berl) 132 (1997) 107-124
15. Denenberg V.H. Open-field behavior in the rat: what does it mean?. Ann N Y Acad Sci 159 (1969) 852-859
16. Dumont Y., Fournier A., St-Pierre S., and Quirion R. Autoradiographic distribution of [125I]Leu31, [Pro34]PYY and [125I]PYY3-36 binding sites in the rat brain evaluated with two newly developed Y1 and Y2 receptor radioligands. Synapse 22 (1996) 139-158
17. Ellenbroek B.A., and Cools A.R. Animal models with construct validity for schizophrenia. Behav Pharmacol 1 (1990) 469-490
18. File S.E. How good is social interaction as a test of anxiety?. In: Simon P., Soubrié P., and Wildlocher D. (Eds). Animal models of psychiatric disorders. Selected models of anxiety, depression and psychosis (1988), Karger, Basel, München, Paris, London, New York, New Delhi, Singapore, Tokyo, and Sydney 151-166
19. File S.E., and Seth P. A review of 25 years of the social interaction test. Eur J Pharmacol 463 (2003) 35-53
20. Geyer M.A., Krebs-Thomson K., Braff D.L., and Swerdlow N.R. Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia: a decade in review. Psychopharmacology (Berl) 156 (2001) 117-154
21. Geyer MA, Swerdlow NR. Measurement of startle response, prepulse inhibition, and habituation. In: Crawley JN, Skolnick P, editors. Current protocols in neuroscience. New York; 1998, p. 8.7.1-15
22. Gray L., van den Buuse M., Scarr E., Dean B., and Hannan A.J. Clozapine reverses schizophrenia-related behaviours in the metabotropic glutamate receptor 5 knockout mouse: association with N-methyl-D-aspartic acid receptor up-regulation. Int J Neuropsychopharmacol 12 (2009) 45-60
23. Greco B., and Carli M. Reduced attention and increased impulsivity in mice lacking NPY Y2 receptors: relation to anxiolytic-like phenotype. Behav Brain Res 169 (2006) 325-334
24. Ikeda K., Ikeda K., Iritani S., Ueno H., and Niizato K. Distribution of neuropeptide Y interneurons in the dorsal prefrontal cortex of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 379-383
25. Itokawa M., Arai M., Kato S., Ogata Y., Furukawa A., Haga S., et al. Association between a novel polymorphism in the promoter region of the neuropeptide Y gene and schizophrenia in humans. Neurosci Lett 347 (2003) 202-204
26. Karl T., Burne T.H., and Herzog H. Effect of Y1 receptor deficiency on motor activity, exploration, and anxiety. Behav Brain Res 167 (2006) 87-93
27. Karl T., Lin S., Schwarzer C., Sainsbury A., Couzens M., Wittmann W., et al. Y1 receptors regulate aggressive behavior by modulating serotonin pathways. Proc Natl Acad Sci USA 101 (2004) 12742-12747
28. Karl T., Pabst R., and von Horsten S. Behavioral phenotyping of mice in pharmacological and toxicological research. Exp Toxicol Pathol 55 (2003) 69-83
29. Kask A., Nguyen H.P., Pabst R., and von Horsten S. Factors influencing behavior of group-housed male rats in the social interaction test: focus on cohort removal. Physiol Behav 74 (2001) 277-282
30. Kuromitsu J., Yokoi A., Kawai T., Nagasu T., Aizawa T., Haga S., et al. Reduced neuropeptide Y mRNA levels in the frontal cortex of people with schizophrenia and bipolar disorder. Gene Exp Patterns 1 (2001) 17-21
31. Lindberg C., Koefoed P., Hansen E.S., Bolwig T.G., Rehfeld J.F., Mellerup E., et al. No association between the -399 C > T polymorphism of the neuropeptide Y gene and schizophrenia, unipolar depression or panic disorder in a Danish population. Acta Psychiatr Scand 113 (2006) 54-58
32. Long L.E., Malone D.T., and Taylor D.A. Cannabidiol reverses MK-801-induced disruption of prepulse inhibition in mice. Neuropsychopharmacology 31 (2006) 795-803
33. Manahan-Vaughan D., von Haebler D., Winter C., Juckel G., and Heinemann U. A single application of MK801 causes symptoms of acute psychosis, deficits in spatial memory, and impairment of synaptic plasticity in rats. Hippocampus 18 (2008) 125-134
34. Miyakawa T., Leiter L.M., Gerber D.J., Gainetdinov R.R., Sotnikova T.D., Zeng H., et al. Conditional calcineurin knockout mice exhibit multiple abnormal behaviors related to schizophrenia. Proc Natl Acad Sci USA 100 (2003) 8987-8992
35. O'Tuathaigh C.M., O'Connor A.M., O'Sullivan G.J., Lai D., Harvey R., Croke D.T., et al. Disruption to social dyadic interactions but not emotional/anxiety-related behaviour in mice with heterozygous 'knockout' of the schizophrenia risk gene neuregulin-1. Prog Neuropsychopharmacol Biol Psychiatry 32 (2007) 462-466
36. Obuchowicz E., Krysiak R., and Herman Z.S. Does neuropeptide Y (NPY) mediate the effects of psychotropic drugs?. Neurosci Biobehav Rev 28 (2004) 595-610
37. Painsipp E., Herzog H., and Holzer P. Implication of neuropeptide-Y Y2 receptors in the effects of immune stress on emotional, locomotor and social behavior of mice. Neuropharmacology 55 (2008) 117-126
38. Powell C.M., and Miyakawa T. Schizophrenia-relevant behavioural testing in rodent models: a uniquely human disorder?. Biol Psychiatry 59 (2006) 1198-1207
39. Redrobe J.P., Dumont Y., Herzog H., and Quirion R. Characterization of neuropeptide Y, Y(2) receptor knockout mice in two animal models of learning and memory processing. J Mol Neurosci 22 (2004) 159-166
40. Sams-Dodd F. Phencyclidine-induced stereotyped behaviour and social isolation in rats: a possible animal model of schizophrenia. Behav Pharmacol 7 (1996) 3-23
41. Swerdlow N.R., and Geyer M.A. Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia. Schizophr Bull 24 (1998) 285-301
42. Tasan R.O., Lin S., Hetzenauer A., Singewald N., Herzog H., and Sperk G. Increased novelty-induced motor activity and reduced depression-like behavior in neuropeptide Y (NPY)-Y4 receptor knockout mice. Neuroscience 158 (2008) 1717-1730
43. Tschenett A., Singewald N., Carli M., Balducci C., Salchner P., Vezzani A., et al. Reduced anxiety and improved stress coping ability in mice lacking NPY-Y2 receptors. Eur J Neurosci 18 (2003) 143-148
44. van den Buuse M., van Driel I.R., Samuelson L.C., Pijnappel M., and Martin S. Reduced effects of amphetamine on prepulse inhibition of startle in gastrin-deficient mice. Neurosci Lett 373 (2005) 237-242
45. Varty G.B., Walters N., Cohen-Williams M., and Carey G.J. Comparison of apomorphine, amphetamine and dizocilpine disruptions of prepulse inhibition in inbred and outbred mice strains. Eur J Pharmacol 424 (2001) 27-36
46. Vezzani A., and Sperk G. Overexpression of NPY and Y2 receptors in epileptic brain tissue: an endogenous neuroprotective mechanism in temporal lobe epilepsy?. Neuropeptides 38 (2004) 245-252
47. Wang J.H., Short J., Ledent C., Lawrence A.J., and van den Buuse M. Reduced startle habituation and prepulse inhibition in mice lacking the adenosine A2A receptor. Behav Brain Res 143 (2003) 201-207